Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$679K-85.6%$4.72M+571%
$1.28M+281%$336K-12.8%
$1.96M-61.2%$5.05M+364%
$1.96M-61.2%$5.05M+364%
-$1.96M+61.2%-$5.05M-364%
-$2.54M+49.6%-$5.05M+33.4%
-$0.05+54.5%-$0.11+50.6%
-$0.05+54.5%-$0.11+50.6%
47.2M+6.5%45.4M+32.8%44.3M
47.2M+6.5%45.4M+32.8%44.3M
$586K+101%$291K$291K$291K$291K

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Polaryx Therapeutics, Inc. profitable?
Polaryx Therapeutics, Inc. is not currently profitable: it reported a net loss of $22.8M over the trailing twelve months.
What is Polaryx Therapeutics, Inc. 's earnings per share?
Polaryx Therapeutics, Inc. 's diluted EPS over the trailing twelve months is $-0.60.
Where does Polaryx Therapeutics, Inc. 's income statement data come from?
Every line is extracted from Polaryx Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.